Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, first-in-human, safety trial of AT-1501 in healthy volunteers and patients with Amyotrophic Lateral Sclerosis (ALS)

Next Previous
Trial Profile

A phase I, first-in-human, safety trial of AT-1501 in healthy volunteers and patients with Amyotrophic Lateral Sclerosis (ALS)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegoprubart (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 16 Aug 2023 According to an Eledon Pharmaceuticals media release, company will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.
    • 05 May 2021 According to an Eledon Pharmaceuticals media release, data from this study will be presented at the virtual American Transplant Congress (ATC) meeting, June 4-9, 2021.
    • 18 Nov 2019 According to an Anelixis Therapeutics media release, the company plans to present data from this trial at an upcoming scientific meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top